Activity Rationale and Purpose

Malignant melanoma represents 2% of all cancers in the United States, and its incidence is increasing. Metastatic melanoma is incurable, and patient survival is often brief. Standard chemotherapy currently consists of dacarbazine, with a response rate of approximately 15%. Combination chemotherapy with dacarbazine has not yielded improved response or survival benefits. The need for improved treatment options has led to consideration of the role of immunomodulatory agents in the treatment of metastatic malignant melanoma. Oncology health care professionals need to be aware of the latest therapeutic options and clinical outcomes. The overall purpose of this educational activity is to provide the latest clinical information on the role of immunomodulatory agents in the treatment of metastatic melanoma.